Skip to main content

World Over 200,000 people vaccinated with Merck Ebola vaccine, Congolese government says

Congolese authorities and health workers vaccinated more than 200,000 people against Ebola in August, the government said on Sunday, using a Merck vaccine they hope will help rein in the world’s second worst epidemic.

Figures released by the government’s Ebola committee showed that 204,044 people had been inoculated since August 8. A total of 1,980 people have so far died in this epidemic, of 2,950 people suspected to have been infected – clinically confirmed cases are a little lower, at 2,845.

It remains the second biggest death toll in the disease’s history, after a 2014-16 outbreak in West Africa that killed 11,300 people.

Story continues below advertisement

The U.S. Department of Health and Human Services (HHS) said on Wednesday it will fund the manufacturing of Merck & Co Inc’s investigational Ebola vaccine called V920. Another vaccine by Johnson and Johnson is available but authorities have yet to deploy it for fear of creating confusion among an already sceptical and sometimes hostile population.

“The only vaccine that has been used in this epidemic is (the one) ... manufactured by Merck,” the committee statement said.

Ebola appears to be under control in the city of Goma in Congo but it has flared in other parts of the country, where aid workers are combatting insecurity and misinformation on social media.

Our Morning Update and Evening Update newsletters are written by Globe editors, giving you a concise summary of the day’s most important headlines. Sign up today.

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter